Gritstone bio
Gritstone Bio, Inc., a US-based biotech firm, specializes in producing and distributing cancer care drugs.
Founded
2015Gritstone Bio, Inc., a US-based biotech firm, specializes in producing and distributing cancer care drugs.
Gritstone bio, Inc., founded in August 2015 and based in Emeryville, California, is a clinical-stage American biotechnology company. Its core mission is to develop groundbreaking immunotherapies for cancers and infectious diseases by leveraging the natural power of a patient’s immune system. The company focuses on generating therapeutic immune responses to recognize and destroy tumors or virally infected cells. Gritstone bio offers cancer care drugs and is also developing vaccines, including a second-generation SARS-CoV-2 vaccine.
Notable affiliated individuals include its founders and key scientific advisors, who are leaders in oncology and immunotherapy. In September 2021, Gritstone bio raised $55 million from the sale of 5,000,000 shares, highlighting strong investor confidence. The company has initiated several clinical trials, including a Phase 1 trial for its self-amplifying mRNA SARS-CoV-2 vaccine. Gritstone bio's innovative approach has the potential to significantly impact cancer treatment and infectious disease management, positioning it as a pioneering force in the biotech industry.
Companies similar to Gritstone bio include Grit Bio, Iovance Biotherapeutics, Gitr and Grail.
Gritstone bio was founded in 2015.
Gritstone bio's headquarters is located in Emeryville, CA, US.
Gritstone bio's most recent funding round was for $80M (USD) in July 2022.
As of Jul 22, 2022, Gritstone bio has disclosed funding of $571.6M (USD). Undisclosed round amounts are excluded.
Gritstone bio has 233 employees as of Feb 6, 2024.
grail.com
